Total knee replacement and chemical thromboprophylaxis: current evidence

Area of Science:

• Orthopedic Surgery
• Vascular Medicine
• Pharmacology

Background:

• Thromboembolic disease, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant risk following elective total knee replacement (TKR).
• Untreated patients have a high incidence of venographically confirmed DVT (40-85%) and a risk of fatal PE (0.1-1.7%).
• Adequate antithrombotic prophylaxis is essential for patients undergoing elective TKR.

Purpose of the Study:

• To review current evidence on chemical thromboprophylaxis after total knee replacement surgery.
• To summarize and compare clinical guidelines from major orthopedic and medical organizations (AAOS, ACCP, NICE).
• To discuss the efficacy of newer oral anticoagulants and emerging strategies for venous thromboembolism (VTE) prevention post-TKR.

Main Methods:

• Review of current scientific literature and clinical evidence.
• Analysis of established clinical guidelines from the American Academy of Orthopaedic Surgeons (AAOS), American College of Chest Physicians (ACCP), and UK's National Institute for Health and Clinical Excellence (NICE).
• Evaluation of recent developments in pharmacological VTE prophylaxis, including new oral anticoagulants.

Main Results:

• Significant variation exists in recommendations across different clinical guidelines regarding VTE prophylaxis post-TKR.
• Newer oral anticoagulants are being investigated for their role in effective VTE prevention.
• Ongoing research aims to identify the most effective and safest thromboprophylaxis strategies after TKR.

Conclusions:

• Effective chemical thromboprophylaxis is crucial to mitigate the risks of DVT and PE after TKR.
• Understanding and comparing different guideline recommendations is important for clinical decision-making.
• The field is evolving with new anticoagulants and strategies to optimize VTE prevention in TKR patients.